Jay and Pamela have a rare condition called Osteogenesis Imperfecta type III. This condition and their experience living with ...

JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025Alvelestat granted ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatmen ...

JPMorgan initiated coverage of Mereo BioPharma (MREO) with an Overweight rating and $7 price target The company’s company’s current valuation ...

TLC stars Jay Manuel and Pamela Chavez are looking to prove Jay’s family wrong as they express their doubts that the couple ...

(Editor’s note: The Clay case, and The Vanguard’s coverage of it, is part of an ongoing investigation.) FAIRFIELD, CA – A ...

"The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) is set to read out at the upcoming second interim analysis mid-year or at the final analysis during the fourth quarter of 2025.

Jay & Pamela” want to get married and live on their own but the couple keeps running into obstacles. A new episode of “Jay & ...

A woman with severe sight loss has said she is losing sleep over changes to the welfare system announced by the UK government ...